In new independent research reports released early this morning,
Capital Review released its latest key findings for all current
investors, traders, and shareholders of Canopy Growth Corporation
(NYSE:CGC), Aimmune Therapeutics, Inc. (NASDAQ:AIMT), Nektar
Therapeutics (NASDAQ:NKTR), Workday, Inc. (NASDAQ:WDAY), Workiva
Inc. (NYSE:WK), and MAG Silver Corporation (NYSE:MAG), including
updated fundamental summaries, consolidated fiscal reporting, and
fully-qualified certified analyst research.
Complimentary Access: Research Reports
Full copies of recently published reports are available
to readers at the links below.
CGC DOWNLOAD: http://Capital-Review.com/register/?so=CGC
AIMT DOWNLOAD: http://Capital-Review.com/register/?so=AIMT NKTR
DOWNLOAD: http://Capital-Review.com/register/?so=NKTR WDAY
DOWNLOAD: http://Capital-Review.com/register/?so=WDAY WK DOWNLOAD:
http://Capital-Review.com/register/?so=WK MAG DOWNLOAD:
http://Capital-Review.com/register/?so=MAG
(You may have to copy and paste the link into your browser and
hit the [ENTER] key)
The new research reports from Capital Review,
available for free download at the links above, examine Canopy
Growth Corporation (NYSE:CGC), Aimmune Therapeutics, Inc.
(NASDAQ:AIMT), Nektar Therapeutics (NASDAQ:NKTR), Workday, Inc.
(NASDAQ:WDAY), Workiva Inc. (NYSE:WK), and MAG Silver Corporation
(NYSE:MAG) on a fundamental level and outlines the overall demand
for their products and services in addition to an in-depth review
of the business strategy, management discussion, and overall
direction going forward. Several excerpts from the recently
released reports are available to today's readers below.
-----------------------------------------
Important Notice: the following
excerpts are not designed to be standalone summaries and as such,
important information may be missing from these samples. Please
download the entire research report, free of charge, to ensure you
are reading all relevant material information. All information in
this release was accessed March 1st, 2019. Percentage calculations
are performed after rounding. All amounts in millions (MM), except
per share amounts.
-----------------------------------------
CANOPY GROWTH CORPORATION (CGC) REPORT
OVERVIEW
Canopy Growth's Recent Financial
Performance
For the three months ended December 31st, 2018
vs December 31st, 2017, Canopy Growth reported revenue of $62.79MM
vs $40.47MM (up 55.16%) and analysts estimated basic earnings per
share $0.17 vs $0.01 (up 2,005.06%). For the twelve months ended
March 31st, 2018 vs March 31st, 2017, Canopy Growth reported
revenue of $139.07MM vs $76.15MM (up 82.64%) and analysts estimated
basic earnings per share -$0.31 vs -$0.11. Analysts expect earnings
to be released on June 26th, 2019. The report will be for the
fiscal period ending March 31st, 2019. The reported EPS for the
same quarter last year was -$0.10. The estimated EPS forecast for
the next fiscal year is -$0.41 and is expected to report on June
26th, 2019.
To read the full Canopy Growth Corporation (CGC) report,
download it here:
http://Capital-Review.com/register/?so=CGC
-----------------------------------------
AIMMUNE THERAPEUTICS, INC. (AIMT) REPORT
OVERVIEW
Aimmune Therapeutics' Recent Financial
Performance
Analysts expect earnings to be released on May
14th, 2019. The report will be for the fiscal period ending March
31st, 2019. Reported EPS for the same quarter last year was -$0.92.
The estimated EPS forecast for the next fiscal year is -$1.95 and
is expected to report on February 27th, 2020.
To read the full Aimmune Therapeutics, Inc. (AIMT) report,
download it here:
http://Capital-Review.com/register/?so=AIMT
-----------------------------------------
NEKTAR THERAPEUTICS (NKTR) REPORT OVERVIEW
Nektar Therapeutics' Recent Financial
Performance
For the three months ended September 30th, 2018
vs September 30th, 2017, Nektar Therapeutics reported revenue of
$27.76MM vs $152.93MM (down 81.85%) and analysts estimated basic
earnings per share -$0.56 vs $0.39. For the twelve months ended
December 31st, 2017 vs December 31st, 2016, Nektar Therapeutics
reported revenue of $307.71MM vs $165.44MM (up 86.00%) and analysts
estimated basic earnings per share -$0.62 vs -$1.10. Analysts
expect earnings to be released on May 9th, 2019. The report will be
for the fiscal period ending March 31st, 2019. Reported EPS for the
same quarter last year was -$0.60. The estimated EPS forecast for
the next fiscal year is -$2.41 and is expected to report on
February 27th, 2020.
To read the full Nektar Therapeutics (NKTR) report, download it
here:
http://Capital-Review.com/register/?so=NKTR
-----------------------------------------
WORKDAY, INC. (WDAY) REPORT OVERVIEW
Workday's Recent Financial Performance
For the three months ended October 31st, 2018 vs
October 31st, 2017, Workday reported revenue of $743.19MM vs
$555.39MM (up 33.81%) and basic earnings per share -$0.70 vs
-$0.41. For the twelve months ended January 31st, 2018 vs January
31st, 2017, Workday reported revenue of $2,143.05MM vs $1,574.44MM
(up 36.12%) and analysts estimated basic earnings per share -$1.55
vs -$1.94. Analysts expect earnings to be released on May 30th,
2019. The report will be for the fiscal period ending April 30th,
2019. The reported EPS for the same quarter last year was -$0.19.
The estimated EPS forecast for the next fiscal year is -$0.96 and
is expected to report on February 27th, 2020.
To read the full Workday, Inc. (WDAY) report, download it here:
http://Capital-Review.com/register/?so=WDAY
-----------------------------------------
WORKIVA INC. (WK) REPORT OVERVIEW
Workiva's Recent Financial Performance
For the three months ended December 31st, 2018
vs December 31st, 2017, Workiva reported revenue of $64.44MM vs
$54.51MM (up 18.22%) and analysts estimated basic earnings per
share -$0.18 vs -$0.34. For the twelve months ended December 31st,
2018 vs December 31st, 2017, Workiva reported revenue of $244.34MM
vs $207.87MM (up 17.55%) and analysts estimated basic earnings per
share -$1.15 vs -$1.07. Analysts expect earnings to be released on
May 1st, 2019. The report will be for the fiscal period ending
March 31st, 2019. The reported EPS for the same quarter last year
was -$0.22. The estimated EPS forecast for the next fiscal year is
-$0.92 and is expected to report on February 19th, 2020.
To read the full Workiva Inc. (WK) report, download it here:
http://Capital-Review.com/register/?so=WK
-----------------------------------------
MAG SILVER CORPORATION (MAG) REPORT
OVERVIEW
MAG Silver's Recent Financial Performance
Analysts expect earnings to be released on March
25th, 2019. The report will be for the fiscal period ending
December 31st, 2018. The reported EPS for the same quarter last
year was -$0.05. The estimated EPS forecast for the next fiscal
year is -$0.06 and is expected to report on March 25th, 2019.
To read the full MAG Silver Corporation (MAG) report, download
it here:
http://Capital-Review.com/register/?so=MAG
-----------------------------------------
ABOUT CAPITAL REVIEW
Capital Review is a nationally recognized
publisher of financial analysis, research reports, and exclusive
market reporting. Institutional investors, registered brokers,
professional traders, and personal investment advisers rely on
Capital Review to quantify public company valuations, discover
opportunity across asset classes, stay informed about market-moving
events, and read exclusive analysis of important material
developments. With 14 offices worldwide, Capital Review staffs and
manages certified and registered financial professionals, including
Chartered Financial Analyst® (CFA®) designation holders and FINRA®
BrokerCheck® certified individuals with current and valid CRD®
number designations, to enable continuous coverage of topics
relevant to its regular active reader base.
REGISTERED MEMBER STATUS
Capital Review's oversight and audit staff are
registered analysts, brokers, and/or financial advisers
("Registered Members") working within Equity Research, Media, and
Compliance departments. Capital Review's roster includes qualified
CFA® charterholders, licensed securities attorneys, and registered
FINRA® members holding duly issued CRD® numbers. Current licensed
status of several Registered Members at Capital Review have been
independently verified by an outside audit firm, including policy
and audit records duly executed by Registered Members. Complaints,
concerns, questions, or inquiries regarding this release should be
directed to Capital Review's Compliance department by Phone, at +1
(410) 280-7496, or by E-mail at compliance@Capital-Review.com.
LEGAL NOTICES
Information contained herein is not an offer or
solicitation to buy, hold, or sell any security. Capital Review,
Capital Review members, and/or Capital Review affiliates are not
responsible for any gains or losses that result from the opinions
expressed. Capital Review makes no representations as to the
completeness, accuracy, or timeliness of the material provided and
all materials are subject to change without notice. Capital Review
has not been compensated for the publication of this press release
by any of the above mentioned companies. Capital Review is not a
financial advisory firm, investment adviser, or broker-dealer, and
does not undertake any activities that would require such
registration. For our full disclaimer, disclosure, and terms of
service please visit our website.
Media Contact: Nicole Garrens, Media Department
Office: +1 (410) 280-7496 E-mail: media@Capital-Review.com
© 2019 Capital Review. All Rights Reserved. For
republishing permissions, please contact a partner network manager
at partnership@Capital-Review.com.
CFA® and Chartered Financial Analyst® are registered
trademarks owned by CFA Institute.
FINRA®, BrokerCheck®, and CRD® are registered trademarks
owned by Financial Industry Regulatory Authority, Inc.
MAG Silver (AMEX:MAG)
Historical Stock Chart
From Aug 2024 to Sep 2024
MAG Silver (AMEX:MAG)
Historical Stock Chart
From Sep 2023 to Sep 2024